Publications by authors named "L Pironi"
Background And Aims: A limited number of randomized controlled trials (RCTs) have examined the use of lipid emulsions (LEs) of different compositions in home parenteral nutrition (HPN), and there are very few data on the long-term use of omega-3 (n-3) polyunsaturated fatty acids (PUFAs). The study's objective was to assess safety and tolerability of an n-3 PUFA-enriched LE in adult patients suffering from chronic intestinal failure (CIF) requiring long-term HPN.
Methods: In this prospective, randomized, controlled, double-blind, multicentre, international clinical trial, which was conducted at eleven sites, adult patients in need of HPN including lipids received either the investigational product, an n-3 PUFA-enriched medium/long-chain triglyceride (MCT/LCT) LE, or the reference product, a standard MCT/LCT LE, for an average duration of eight weeks.
Liver transplantation (LT) associates with weight gain and metabolic complications. However, risk of eating disorders post-transplantation and factors influencing their onset remain poorly understood. This study aimed to fill this knowledge gap by characterizing the risk of having eating disorders or Orthorexia Nervosa (ON) according to the EAT-26, BES and Bratman screening questionnaires in 104 liver transplant recipients (mean age 62.
View Article and Find Full Text PDFArticle Synopsis
- Researchers discovered a recessive syndrome linked to mutations in the DNA ligase 3 (LIG3) gene that causes chronic intestinal pseudo-obstruction and other neurological issues due to impaired mitochondrial DNA maintenance and energy production.
- They performed whole transcriptome analysis on patient fibroblasts, finding deregulated genes related to mitochondrial function and extracellular matrix development, and tested l-glutamine supplementation to address energy impairments.
- Treatment with l-glutamine significantly improved the symptoms of patients with LIG3 mutations, highlighting its potential as a targeted therapy for mitochondrial dysfunction related to this condition.*
Background: Cross-sectional plasma citrulline concentration (CIT) is considered a marker of enterocyte mass. The role of CIT in clinical practice in patients with short bowel syndrome (SBS) is not clearly defined.
Aim: To assess the accuracy of CIT to discriminate SBS from healthy controls (HC) and SBS with intestinal failure (SBS-IF), requiring intravenous supplementation (IVS), from SBS with intestinal insufficiency (SBS-II).